drugset / Trial / NCT00741455
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine disease-free survival, overall survival, time to progression, regimen-related toxicity and/or treatment-related mortality in patients with hematologic malignancies treated with non-myeloablative chemotherapy followed by allogeneic stem cell transplant.
Timeline
- Start
- 2004-06
- Primary completion
- 2020-05-01
- Completion
- 2020-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclophosphamide | Other / unclassified | 1 g | Intravenous |
| Background | Cyclosporine | Peptide | — | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |
| Background | G-CSF | Unknown | 10 ug/kg | — |
| Background | Methotrexate | Small molecule | — | — |